LIVIVO - Search results -

Search results

Result 1 - 10 of total 40

Search options

Article ; Online: Prostate specific antigen in COVID-19 patients.

Di Vincenzo, Angelo / Busetto, Luca / Vettor, Roberto / Rossato, Marco

2021 Volume 9, Issue 4, Page(s) 1042

MeSH term(s)	COVID-19 ; Humans ; Male ; Prostate-Specific Antigen ; Prostatic Neoplasms ; SARS-CoV-2
Chemical Substances	Prostate-Specific Antigen (EC 3.4.21.77)
Language	English
Publishing date	2021-03-04
Publishing country	England
Document type	Letter ; Comment
ZDB-ID	2696108-8
ISSN	2047-2927 ; 2047-2919
ISSN (online)	2047-2927
ISSN	2047-2919
DOI	10.1111/andr.12987
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6983: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: 18F-prostate-specific membrane antigen positron emission tomography computed tomography incidental finding in a patient after COVID-19 infection

Siroos Mirzaei / Cherin Farhan / Mario Karolyi

World Journal of Nuclear Medicine, Vol 19, Iss 04, Pp 455-

2020 Volume 456

Abstract: The COVID-19 pandemic has now reached most countries. However, the referred patients ... male) who was sent for 18F-prostate-specific membrane antigen positron emission tomography computed ... years prior to the examination. He suffered from COVID-19 pneumonia 4 weeks prior to PET-CT examination ...

Abstract	The COVID-19 pandemic has now reached most countries. However, the referred patients to a nuclear medicine department will be primarily the asymptomatic ones. We report the case of a patient (84-year-old male) who was sent for 18F-prostate-specific membrane antigen positron emission tomography computed tomography (PSMA PET-CT) with suspicion of recurrent disease after prostate cancer and total prostatectomy 2 years prior to the examination. He suffered from COVID-19 pneumonia 4 weeks prior to PET-CT examination. The 18F-PSMA PET-CT revealed moderate elevated uptake in the area of previous pneumonia in the right lung. The radiological findings showed ground glass changes in this area indicating possible residual inflammatory disease even weeks after infection.
Keywords	18f-prostate-specific membrane antigen ; covid-19 ; infection ; positron emission tomography computed tomography ; prostate cancer ; Medical physics. Medical radiology. Nuclear medicine ; R895-920
Subject code	570
Language	English
Publishing date	2020-10-01T00:00:00Z
Publisher	Wolters Kluwer Medknow Publications
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: 18F-prostate-specific membrane antigen positron emission tomography computed tomography incidental finding in a patient after COVID-19 infection

Mirzaei, Siroos / Farhan, Cherin / Karolyi, Mario

World Journal of Nuclear Medicine

2020 Volume 19, Issue 04, Page(s) 455–456

Abstract: The COVID-19 pandemic has now reached most countries. However, the referred patients ... male) who was sent for 18 F-prostate-specific membrane antigen positron emission tomography computed ... years prior to the examination. He suffered from COVID-19 pneumonia 4 weeks prior to PET-CT examination ...

Abstract	The COVID-19 pandemic has now reached most countries. However, the referred patients to a nuclear medicine department will be primarily the asymptomatic ones. We report the case of a patient (84-year-old male) who was sent for 18 F-prostate-specific membrane antigen positron emission tomography computed tomography (PSMA PET-CT) with suspicion of recurrent disease after prostate cancer and total prostatectomy 2 years prior to the examination. He suffered from COVID-19 pneumonia 4 weeks prior to PET-CT examination. The 18 F-PSMA PET-CT revealed moderate elevated uptake in the area of previous pneumonia in the right lung. The radiological findings showed ground glass changes in this area indicating possible residual inflammatory disease even weeks after infection.
Keywords	F-prostate-specific membrane antigen ; COVID-19 ; infection ; positron emission tomography computed tomography ; prostate cancer
Language	English
Publishing date	2020-10-01
Publisher	Thieme Medical and Scientific Publishers Pvt. Ltd.
Publishing place	Stuttgart ; New York
Document type	Article
ZDB-ID	2911903-0
ISSN	1607-3312 ; 1450-1147
ISSN (online)	1607-3312
ISSN	1450-1147
DOI	10.4103/wjnm.WJNM_110_20
Database	Thieme publisher's database

In stock of ZB MED Cologne/Königswinter

Zs.A 7137: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: 18F-prostate-specific membrane antigen positron emission tomography computed tomography incidental finding in a patient after COVID-19 infection

Mirzaei, Siroos / Farhan, Cherin / Karolyi, Mario

World Journal of Nuclear Medicine

2020

Keywords	covid19
Language	English
Publisher	Medknow
Publishing country	in
Document type	Article ; Online
ZDB-ID	2911903-0
ISSN	1607-3312 ; 1450-1147
ISSN (online)	1607-3312
ISSN	1450-1147
DOI	10.4103/wjnm.wjnm_110_20
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Zs.A 7137: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial.

Nam, Robert / Patel, Chirag / Milot, Laurent / Hird, Amanda / Wallis, Christopher / Macinnis, Patrick / Singh, Mala / Emmenegger, Urban / Sherman, Christopher / Haider, Masoom A

BMJ open

2022 Volume 12, Issue 11, Page(s) e059482

Abstract: ... execution during the COVID-19 pandemic, the study was terminated early. In the PSA arm, 48 patients had ... Patients were recommended to undergo a prostate biopsy if their PSA was ≥2.6 ng/mL (PSA arm) or if they had ... an abnormal PSA and 28 (58%) agreed to undergo a prostate biopsy. In the MRI arm, 25 patients had a PIRADS ...

Abstract	Objectives: Our objective was to compare prostate cancer detection rates between patients undergoing serum prostate-specific antigen (PSA) vs magnetic resonance imaging (MRI) for prostate cancer screening. Design: Phase III open-label randomised controlled trial. Setting: Single tertiary cancer centre in Toronto, Canada. Participants: Men 50 years of age and older with no history of PSA screening for ≥3 years, a negative digital rectal exam and no prior prostate biopsy. Interventions: Patients were recommended to undergo a prostate biopsy if their PSA was ≥2.6 ng/mL (PSA arm) or if they had a PIRADS score of 4 or 5 (MRI arm). Patients underwent an end-of-study PSA in the MRI arm. Primary and secondary outcome measures: Adenocarcinoma on prostate biopsy. Prostate biopsy rates and the presence of clinically significant prostate cancer were also compared. Results: A total of 525 patients were randomised, with 266 in the PSA arm and 248 in the MRI arm. Due to challenges with accrual and study execution during the COVID-19 pandemic, the study was terminated early. In the PSA arm, 48 patients had an abnormal PSA and 28 (58%) agreed to undergo a prostate biopsy. In the MRI arm, 25 patients had a PIRADS score of 4 or 5 and 24 (96%) agreed to undergo a biopsy. The relative risk for MRI to recommend a prostate biopsy was 0.52 (95% CI 0.33 to 0.82, p=0.005), compared with PSA. The cancer detection rate for patients in the PSA arm was 29% (8 of 28) vs 63% (15 of 24, p=0.019) in the MRI arm, with a higher proportion of clinically significant cancer detected in the MRI arm (73% vs 50%). The relative risk for detecting cancer and clinically significant with MRI compared with PSA was 1.89 (95% CI 0.82 to 4.38, p=0.14) and 2.77 (95% CI 0.89 to 8.59, p=0.07), respectively. Conclusions: Prostate MRI as a stand-alone screening test reduced the rate of prostate biopsy. The number of clinically significant cancers detected was higher in the MRI arm, but this did not reach statistical significance. Due to early termination, the study was underpowered. More patients were willing to follow recommendations for prostate biopsy based on MRI results. Trial registration number: NCT02799303.
MeSH term(s)	Male ; Humans ; Prostatic Neoplasms/diagnostic imaging ; Prostate-Specific Antigen ; Prostate/diagnostic imaging ; Prostate/pathology ; Early Detection of Cancer/methods ; Pandemics ; COVID-19 ; Magnetic Resonance Imaging
Chemical Substances	Prostate-Specific Antigen (EC 3.4.21.77)
Language	English
Publishing date	2022-11-08
Publishing country	England
Document type	Randomized Controlled Trial ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2599832-8
ISSN	2044-6055 ; 2044-6055
ISSN (online)	2044-6055
ISSN	2044-6055
DOI	10.1136/bmjopen-2021-059482
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study)

Urban Emmenegger / Chirag Patel / Christopher Wallis / Amanda Hird / Christopher Sherman / Robert Nam / Laurent Milot / Patrick Macinnis / Mala Singh / Masoom A Haider

BMJ Open, Vol 12, Iss

a randomised clinical trial

2022 Volume 11

Abstract: ... a negative digital rectal exam and no prior prostate biopsy.Interventions Patients were recommended ... to undergo a prostate biopsy. In the MRI arm, 25 patients had a PIRADS score of 4 or 5 and 24 (96%) agreed ... Objectives Our objective was to compare prostate cancer detection rates between patients undergoing ...

Abstract	Objectives Our objective was to compare prostate cancer detection rates between patients undergoing serum prostate-specific antigen (PSA) vs magnetic resonance imaging (MRI) for prostate cancer screening.Design Phase III open-label randomised controlled trial.Setting Single tertiary cancer centre in Toronto, Canada.Participants Men 50 years of age and older with no history of PSA screening for ≥3 years, a negative digital rectal exam and no prior prostate biopsy.Interventions Patients were recommended to undergo a prostate biopsy if their PSA was ≥2.6 ng/mL (PSA arm) or if they had a PIRADS score of 4 or 5 (MRI arm). Patients underwent an end-of-study PSA in the MRI arm.Primary and secondary outcome measures Adenocarcinoma on prostate biopsy. Prostate biopsy rates and the presence of clinically significant prostate cancer were also compared.Results A total of 525 patients were randomised, with 266 in the PSA arm and 248 in the MRI arm. Due to challenges with accrual and study execution during the COVID-19 pandemic, the study was terminated early. In the PSA arm, 48 patients had an abnormal PSA and 28 (58%) agreed to undergo a prostate biopsy. In the MRI arm, 25 patients had a PIRADS score of 4 or 5 and 24 (96%) agreed to undergo a biopsy. The relative risk for MRI to recommend a prostate biopsy was 0.52 (95% CI 0.33 to 0.82, p=0.005), compared with PSA. The cancer detection rate for patients in the PSA arm was 29% (8 of 28) vs 63% (15 of 24, p=0.019) in the MRI arm, with a higher proportion of clinically significant cancer detected in the MRI arm (73% vs 50%). The relative risk for detecting cancer and clinically significant with MRI compared with PSA was 1.89 (95% CI 0.82 to 4.38, p=0.14) and 2.77 (95% CI 0.89 to 8.59, p=0.07), respectively.Conclusions Prostate MRI as a stand-alone screening test reduced the rate of prostate biopsy. The number of clinically significant cancers detected was higher in the MRI arm, but this did not reach statistical significance. Due to early termination, the study was ...
Keywords	Medicine ; R
Subject code	610
Language	English
Publishing date	2022-11-01T00:00:00Z
Publisher	BMJ Publishing Group
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Patterns of Prostate-Specific Antigen Testing and Prostate Biopsies During the COVID-19 Pandemic.

Kaufman, Harvey W / Chen, Zhen / Niles, Justin K / Radcliff, Jeff / Fesko, Yuri

JCO clinical cancer informatics

2021 Volume 5, Page(s) 1028–1033

Abstract: ... PSA] testing), prostate biopsy testing, and prostate cancer diagnoses during the COVID-19 pandemic ... Purpose: This study examined changes in prostate disease screening (prostatic-specific antigen ... for non-COVID-19-related medical conditions. ...

Abstract	Purpose: This study examined changes in prostate disease screening (prostatic-specific antigen [PSA] testing), prostate biopsy testing, and prostate cancer diagnoses during the COVID-19 pandemic through December 2020. Materials and methods: This analysis included test results from men ≥ 40 years, without prior International Classification of Diseases-10 record of prostate cancer since January 2016, who received PSA or prostate biopsy testing at Quest Diagnostics during January 2018-December 2020. Monthly trends were evaluated for three periods: prepandemic (January 2018-February 2020), early-pandemic (March-May 2020), and late-pandemic (June-December 2020). Results: Meeting inclusion criteria were 16,365,833 PSA and 48,819 prostate biopsy results. The average monthly number of PSA tests declined from 465,187 prepandemic to 295,786 early-pandemic (36.4% decrease; Conclusion: The findings suggest that a substantial number of prostate screening opportunities and cancer diagnoses have been missed. Efforts are needed to bring such patients back for screening and diagnostic testing and to restore appropriate care for non-COVID-19-related medical conditions.
MeSH term(s)	Biopsy ; COVID-19 ; Early Detection of Cancer/statistics & numerical data ; Humans ; Male ; Pandemics ; Prostate ; Prostate-Specific Antigen/analysis ; Prostatic Neoplasms/diagnosis ; Prostatic Neoplasms/epidemiology
Chemical Substances	Prostate-Specific Antigen (EC 3.4.21.77)
Language	English
Publishing date	2021-11-07
Publishing country	United States
Document type	Journal Article
ISSN	2473-4276
ISSN (online)	2473-4276
DOI	10.1200/CCI.21.00074
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The outcomes of same-day discharge following holmium laser enucleation of the prostate (HoLEP) surgeries: our experience during the COVID-19 pandemic.

Badreddine, Jad / Sun, Helen / Tay, Kimberly / Rhodes, Stephen / Chen, Daniel / Zell, Michael / Jaeger, Irina / Nevo, Amihay

World journal of urology

2023 Volume 41, Issue 6, Page(s) 1613–1619

Abstract: ... Enucleation of the Prostate (HoLEP) in patients during the COVID-19 pandemic.: Methods: A retrospective ... prostate-specific antigen (5.7 vs 3.9 ng/dL, P < 0.001), prostate volume (152.3 vs 100.6 mL, P < 0.001), and enucleated ... of 155 patients were identified; 135 patients were successfully discharged on the same day and 20 were ...

Abstract	Objective: To describe the outcomes of Same-Day Discharge (SDD) following Holmium Laser Enucleation of the Prostate (HoLEP) in patients during the COVID-19 pandemic. Methods: A retrospective review of HoLEP surgeries at a single institution between January 2021 and March 2022 was performed. Patient demographic and operative data were collected, and postoperative outcomes were evaluated in terms of safety and efficacy and compared in both groups using a t-test and chi-square test. Logistic regression was also performed to identify factors that correlate with the failure of SDD. Results: A total of 155 patients were identified; 135 patients were successfully discharged on the same day and 20 were admitted (87% SDD rate). Admitted HoLEP patients had a significantly higher median prostate-specific antigen (5.7 vs 3.9 ng/dL, P < 0.001), prostate volume (152.3 vs 100.6 mL, P < 0.001), and enucleated tissue weight (90.3 vs 56.9 g, P = 0.04) compared to the SDD group. The SDD group had a 2.9% (n = 4) readmission rate and a 5.2% (n = 7) Emergency Department (ED) visit rate. There was no significant difference in the rate of postoperative ED visits (P = 0.64), readmissions (P = 0.98), complications, and catheterization time (P = 0.98) between both groups. Preoperative predictors of SDD failure included prostate gland volume > 150 mL (OR = 7.17; CI 2.01-25.67; P < 0.01) and history of antiplatelet/anticoagulation use (OR = 6.59; CI 2.00-21.67; P < 0.01). Conclusion: Same-day discharge following HoLEP is a safe and effective approach that can be performed in most patients using a liberal discharge criteria and relying on postoperative findings only.
MeSH term(s)	Male ; Humans ; Prostate/surgery ; Prostatic Hyperplasia/surgery ; Prostatic Hyperplasia/complications ; Patient Discharge ; Holmium ; Lasers, Solid-State/therapeutic use ; Pandemics ; Treatment Outcome ; Quality of Life ; COVID-19/epidemiology ; COVID-19/complications ; Laser Therapy ; Transurethral Resection of Prostate ; Retrospective Studies
Chemical Substances	Holmium (W1XX32SQN1)
Language	English
Publishing date	2023-05-09
Publishing country	Germany
Document type	Journal Article
ZDB-ID	380333-8
ISSN	1433-8726 ; 0724-4983
ISSN (online)	1433-8726
ISSN	0724-4983
DOI	10.1007/s00345-023-04410-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1832: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Post-Pandemic Aftermath: A Two-Year Follow-Up of the Effect of COVID-19 on Oncological Outcomes after Radical Prostatectomy for Prostate Cancer.

Borz, Mihnea Bogdan / Schitcu, Vlad Horia / Crisan, Nicolae / Petrut, Bogdan / Buhas, Bogdan Adrian / Borz, Paul Cristian / Valean, Dan / Duquesne, Igor / Coman, Ioan

Archivos espanoles de urologia

2024 Volume 77, Issue 1, Page(s) 43–48

Abstract: ... 19) pandemic on the surgical outcomes and oncological results of patients who underwent surgery ... histopathological findings and oncological outcomes, including prostate-specific antigen (PSA) levels and ... The COVID-19 pandemic led to poor postoperative results. Through a 2-year follow-up, this research ...

Abstract	Purpose: This study aimed to evaluate the indirect effect of the Coronavirus Disease 2019 (COVID-19) pandemic on the surgical outcomes and oncological results of patients who underwent surgery during the lockdown period. Methods: We analysed data from 423 patients who underwent radical prostatectomy between 2016 and 2022, with a cut-off date of March 16, 2020. Patients were categorised into two groups, namely, pre-lockdown (n = 289) and during lockdown (n = 134). Perioperative variables, histopathological findings and oncological outcomes, including prostate-specific antigen (PSA) levels and biochemical recurrence (BCR), were assessed. Results: The number of radical prostatectomy increased by 24.26% during lockdown. The study included patients with a mean follow-up of 21 months. A nonsignificant trend towards a higher PSA level at presentation was found (14.22 vs. 12.53 ng/dL, Conclusions: The COVID-19 pandemic led to poor postoperative results. Through a 2-year follow-up, this research investigated the effect of the pandemic on the oncological outcomes, particularly BCR, of patients who underwent radical prostatectomy. Further extended investigations and multi-institutional studies should be conducted to quantify the effect of the pandemic on various cancer outcomes and inform crisis management strategies.
MeSH term(s)	Male ; Humans ; Prostate-Specific Antigen ; Pandemics ; Follow-Up Studies ; COVID-19/epidemiology ; Communicable Disease Control ; Prostatic Neoplasms/epidemiology ; Prostatic Neoplasms/surgery ; Prostatic Neoplasms/pathology ; Prostatectomy/methods ; Retrospective Studies ; Neoplasm Recurrence, Local
Chemical Substances	Prostate-Specific Antigen (EC 3.4.21.77)
Language	English
Publishing date	2024-02-19
Publishing country	Spain
Document type	Journal Article
ZDB-ID	211673-x
ISSN	0004-0614
ISSN	0004-0614
DOI	10.56434/j.arch.esp.urol.20247701.6
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 1312: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Implications and effects of COVID-19 on diagnosis and management of prostate cancer.

Chan, Vinson Wai-Shun / Asif, Aqua / Koe, Jasmine Sze-Ern / Ng, Alexander / Ng, Chi Fai / Teoh, Jeremy Yuen-Chun

Current opinion in urology

2022 Volume 32, Issue 3, Page(s) 311–317

Abstract: ... themselves and their patients.: Summary: COVID-19 transmission during prostate procedures is possible ... general anaesthesia. Patients must also be triaged using preoperative polymerase chain reaction tests for COVID-19 ... the need for prostate biopsy unless when absolutely indicated, and the risk of COVID-19 spread can be ...

Abstract	Purpose of review: The Coronavirus disease 2019 (COVID-19) pandemic has led to uncertainty on the optimal management for prostate cancer (PCa). This narrative review aims to shed light on the optimal diagnosis and management of patients with or suspected to have PCa. Recent findings: Faecal-oral or aerosol transmission is possible during prostate procedures; caution must be in place when performing digital rectal examinations, transrectal ultrasound-guided prostate biopsies and prostate surgeries requiring general anaesthesia. Patients must also be triaged using preoperative polymerase chain reaction tests for COVID-19. COVID-19 has accelerated the adoption of multiparametric Magnetic Resonance Imaging (MRI), reducing the need for prostate biopsy unless when absolutely indicated, and the risk of COVID-19 spread can be reduced. Combined with prostate-specific antigen (PSA) density, amongst other factors, multiparametric MRI could reduce unnecessary biopsies in patients with little chance of clinically significant PCa. Treatment of PCa should be stratified by the risk level and preferences of the patient. COVID-19 has accelerated the development of telemedicine and clinicians should utilise safe and effective teleconsultations to protect themselves and their patients. Summary: COVID-19 transmission during prostate procedures is possible. Patients with a Prostate Imaging-Reporting and Data System (PI-RADS) of <3 and PSA density <0.15 ng/ml/ml are deemed low-risk and are safe to undergo surveillance without MRI-targeted biopsy. Intermediate- or high-risk patients should be offered definitive treatment within four months or 30days of diagnosis to avoid compromising treatment outcomes; three-month courses of neoadjuvant androgen deprivation therapy can be considered when a delay of surgery is anticipated.
MeSH term(s)	Androgen Antagonists ; COVID-19 ; Humans ; Image-Guided Biopsy/methods ; Magnetic Resonance Imaging/methods ; Male ; Prostate-Specific Antigen ; Prostatic Neoplasms/diagnosis ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/therapy ; Retrospective Studies
Chemical Substances	Androgen Antagonists ; Prostate-Specific Antigen (EC 3.4.21.77)
Language	English
Publishing date	2022-02-09
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1091792-5
ISSN	1473-6586 ; 0963-0643
ISSN (online)	1473-6586
ISSN	0963-0643
DOI	10.1097/MOU.0000000000000973
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3345: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito